State of Alaska Department of Revenue Sells 10,403 Shares of Charles River Laboratories International, Inc. $CRL

State of Alaska Department of Revenue decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 65.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,511 shares of the medical research company’s stock after selling 10,403 shares during the quarter. State of Alaska Department of Revenue’s holdings in Charles River Laboratories International were worth $836,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Exchange Traded Concepts LLC increased its holdings in shares of Charles River Laboratories International by 1.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock valued at $871,000 after acquiring an additional 76 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock valued at $589,000 after acquiring an additional 102 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Charles River Laboratories International by 6.8% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 123 shares in the last quarter. Finally, Empirical Finance LLC increased its holdings in shares of Charles River Laboratories International by 10.2% during the first quarter. Empirical Finance LLC now owns 1,442 shares of the medical research company’s stock valued at $217,000 after acquiring an additional 133 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRL has been the subject of several analyst reports. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a report on Friday. William Blair upgraded Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Wall Street Zen lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $179.93.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Performance

CRL stock opened at $175.02 on Tuesday. The company has a market cap of $8.61 billion, a P/E ratio of -131.59, a price-to-earnings-growth ratio of 4.74 and a beta of 1.50. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock’s fifty day moving average price is $159.39 and its 200-day moving average price is $147.22.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same period last year, the business posted $2.80 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).